Zydus Lifesciences announced that it has received final approval from the US FDA for Acyclovir Cream, 5%.
An antiviral, the cream is used to treat cold sores (fever blisters; blisters that are caused by a virus called herpes simplex) on the face or lips. The product will be launched shortly in the US market.
The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India).
Acyclovir Cream, 5% had annual sales of USD 16.9 million in USA (IQVIA MAT Dec. 2022).
The group now has 348 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
The market is happy with this development with the stock price rising 1.5% to hit an intraday high at Rs.472.60, which is not too far from its 52-week high of Rs.482.20, hit on 8th Feb’23.